A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Preliminary Clinical Activity and Immunogenicity of Multiple Doses of MOR103 Administered Intravenously to Patients With Active Rheumatoid Arthritis.

Trial Profile

A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Preliminary Clinical Activity and Immunogenicity of Multiple Doses of MOR103 Administered Intravenously to Patients With Active Rheumatoid Arthritis.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 22 May 2015

At a glance

  • Drugs GSK 3196165 (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions
  • Sponsors MorphoSys
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 14 Nov 2012 Results presented at the 76th Annual Scientific Meeting of the American College of Rheumatology and the 47th Annual Meeting of the Association of Rheumatology and Health Professionals.
    • 06 Nov 2012 Results will be presented in a late-breaking abstract at the 2012 American College for Rheumatology Annual Meeting, according to a MorphoSys media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top